Skip to content

Alinity 08P1021Recalls & reported problems

Abbott Ireland Diagnostics · Alinity i HBsAg Qualitative II Reagent Kit 200 Tests · Class 2

Adverse event reports
4
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 4 adverse event reports that list this exact device (DI 00380740136581), received between May 20, 2022 and Jan 3, 2024 — classified as 4 malfunctions.

The most frequently reported specific device problem is “False Positive Result” (4 reports).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 1 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • False Positive Result4

Patient problems

  • No Clinical Signs, Symptoms or Conditions4

Recent adverse event reports

The 4 most recent of 4 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJan 3, 2024False Positive Result; False Positive Result

    THE CUSTOMER OBSERVED A FALSE REACTIVE ALINITY I HBSAG QUALITATIVE II RESULT FOR A PATIENT IN THE DIALYSIS UNIT. THE FOLLOWING DATA WAS PROVIDED: INITIAL RESULT A WEEK AGO = NEGATIVE, HEP B VACCINE ADMINISTERED. (B)(6) 2023 SAME PATIENT, NEW SAMPLE. RESULT = POSITIVE FOR BOTH HEP B ANTIGEN AND ANTIBODY. SAMPLE ID (B)(6) INITIAL RESULT = REACTIVE. REPEAT IN DUPLICATE AND BOTH RESULTS = REACTIVE. CONFIRMATORY TEST PERFORMED AND RESULT = REACTIVE. NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 18440583 ↗
  • MalfunctionFeb 20, 2023False Positive Result; False Positive Result

    THE CUSTOMER OBSERVED FALSE REACTIVE ALINITY I HBSAG QUALITATIVE II AND ALINITY I HBSAG QUALITATIVE II CONFIRMATORY RESULTS FOR A PREGNANT FEMALE PATIENT. THE SAMPLE WAS PULLED AND REPEATED 4 DAYS LATER WITH A NONREACTIVE RESULT. A SECOND SAMPLE WAS DRAWN WHICH GENERATED A NONREACTIVE RESULT. THE FOLLOWING DATA WAS PROVIDED: CUSTOMER STATED THEY HAD A SAMPLE THAT WAS DRAWN ON (B)(6) 2023 THAT RAN ON (B)(6) 2023 AND GAVE THE FOLLOWING RESULTS ACCORDING TO CUSTOMER: SID (B)(6) HBSAG=1.04 HBSAG CONFIRMATORY = REACTIVE. REPEAT OF SAMPLE ON (B)(6) 2023 SAMPLE WAS RESPUN AND RERAN IN DUPLICATE ACCORDING TO CUSTOMER: HBSAG=1.19, HBSAG=1.27, HBSAG CONFIRMATORY = 1.11 CONFIRMED POSITIVE. SAMPLE WAS RERUN ON (B)(6) 2023, RESULT = SID (B)(6) HBSAG=0.33 NONREACTIVE. NEW SAMPLE DRAWN (B)(6) 2023 SID= (B)(6) HBSAG = NONREACTIVE HBSAG CONFIRMATORY = NEGATIVE. PER ALINITY I HBSAG QUALITATIVE II PACKAGE INSERT < 1.00 NONREACTIVE NO RETEST REQUIRED. = 1.00 REACTIVE RETEST IN DUPLICATE NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 16403034 ↗
  • MalfunctionFeb 20, 2023False Positive Result; False Positive Result

    THE CUSTOMER OBSERVED FALSE REACTIVE ALINITY I HBSAG QUALITATIVE II AND ALINITY I HBSAG QUALITATIVE II CONFIRMATORY RESULTS FOR A PREGNANT FEMALE PATIENT. THE SAMPLE WAS PULLED AND REPEATED 4 DAYS LATER WITH A NONREACTIVE RESULT. A SECOND SAMPLE WAS DRAWN WHICH GENERATED A NONREACTIVE RESULT. THE FOLLOWING DATA WAS PROVIDED: CUSTOMER STATED THEY HAD A SAMPLE THAT WAS DRAWN ON (B)(6) 2023 THAT RAN ON (B)(6) 2023 AND GAVE THE FOLLOWING RESULTS ACCORDING TO CUSTOMER: SID (B)(6) HBSAG=1.04 HBSAG CONFIRMATORY = REACTIVE. REPEAT OF SAMPLE ON (B)(6) 2023 SAMPLE WAS RESPUN AND RERAN IN DUPLICATE ACCORDING TO CUSTOMER: HBSAG=1.19 ; HBSAG=1.27 ; HBSAG CONFIRMATORY = 1.11 CONFIRMED POSITIVE. SAMPLE WAS RERUN ON (B)(6) 2023 RESULT = SID (B)(6) HBSAG=0.33 NONREACTIVE. NEW SAMPLE DRAWN (B)(6) 2023 SID= (B)(6) HBSAG = NONREACTIVE HBSAG CONFIRMATORY = NEGATIVE PER ALINITY I HBSAG QUALITATIVE II PACKAGE INSERT < 1.00 NONREACTIVE NO RETEST REQUIRED. = 1.00 REACTIVE RETEST IN DUPLICATE NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 16402197 ↗
  • MalfunctionMay 20, 2022False Positive Result; False Positive Result

    THE CUSTOMER OBSERVED FALSE REACTIVE ALINITY I HBSAG RESULTS GENERATED ON AN ALINITY I PROCESSING MODULE FOR TWO PATIENTS THAT CONFIRMED POSITIVE AND WERE NEGATIVE ON AN OTHER METHOD. THE FOLLOWING INFORMATION WAS PROVIDED: SID (B)(6) INITIAL RESULT = 1.35 S/CO, REPEAT RESULTS = 1.25 S/CO AND 1.33 S/CO; HBSAG CONFIRMATORY RESULTS: C1 = 0.35 S/CO, C2=1.86 S/CO, NEUT% = 94%. SAMPLE WAS SENT TO REFERENCE LAB AND CAME BACK NEGATIVE ON UNKNOWN METHODOLOGY. SID (B)(6) INITIAL RESULT = 2.63 S/CO, REPEAT RESULTS = 2.74 S/CO AND 2.72 S/CO; HBSAG CONFIRMATORY RESULTS: C2 = 2.31 S/CO, NEUT% = 97% NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 14458054 ↗

Other Test, hepatitis b (b core, be antigen, be antibody, b core igm) devices

All Test, hepatitis b (b core, be antigen, be antibody, b core igm) devices →

Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.